Brind.

Gilead Sciences excluded Latin America and the Caribbean from affordable drug access, prompting denouncement from AHF.

1 report, 1 independent Updated Jul 10

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Gilead Sciences AIDS Healthcare Foundation

Keep exploring

The entities involved

Gilead Sciences
American company
- FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences.Mon 18:04
- Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.Mon 17:32
AIDS Healthcare Foundation
nonprofit organization in Durban, South Africa

Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped

Jul 10Business WireAHF: Gilead’s Greed Costs Latin America HIV Protection MEXICO CITY, July 09, 2025--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America a